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The objective of European Paediatric Formulation Initiative (EuPFI) is to promote 
collaboration between industry, academia, clinical and regulatory professionals to facilitate 
preparation of better and safe dosage forms for children. It provides the platform to discuss 
contemporaneous issues shared by scientific community in developing paediatric medicines.  
In order to achieve these objectives, EuPFI conferences have been successfully held for six 
years. Continuing on its mission, in 2015, EuPFI organised the 7th conference on 
“Formulating better medicines for children” in association with APV (Arbeitsgemeinschaft 
für Pharmaceutische Verfahrenstechnik). It brought together 140 delegates and keynote 
speakers from 23 countries on 16-17th September 2016 in Antwerp, Belgium to present the 
current needs and challenges in paediatric drug development. It highlighted in particular the 
implications from multiple stakeholder perspectives, including regulators, industry 
representatives academics and clinicians. 
 
The programme aimed to focus on key efforts to expedite the crucial development of 
paediatric formulations in a global context and to look into both the clinical and regulatory 
hurdles as well as discuss technological and scientific improvements in paediatric 
formulation research. Interactive preconference workshops organised just before the main 
conference offered the opportunity to profit from expertise on two key topics: “Challenges 
of Administering Medicines to Neonates” and “Constructing & Evaluating Paediatric 
Investigation Plans (PIPs)”. The administration of drugs to neonates poses significant 
challenges. Virginia Aguado Lorenzo (Evelina London Children’ Hospital, UK) provided insight 
into some of these challenges and resolutions that may be encountered with oral and 
parenteral route of administration in neonatal care. The main focus was on the factors such 
as excipients, inaccurate doses, dosage form that have an impact on accurate administration 
of doses routinely prescribed to neonates and practical considerations when administering 
small doses to neonates. The enteral and parenteral administration devices were displayed 
at workstations and the delegates were given a case study on complex method of 
preparation of infusion. An interactive discussion took place on challenges in using the 
devices and methods of dilution, risks and accuracy of concentration of final infusion.  
The second workshop led by Dr Nasir Hussian (MHRA, UK) on constructing & evaluating PIPs 
provided the insights into the challenges faced during the preparation and evaluation of 
PIPs. Three PIP case studies relating to different route of administration – oral, injectable 
and a topical were assigned to three groups.  Aspects discussed included paediatric 
suitability / age-appropriateness of designated PIP case study on quality and 
biopharmaceutical grounds taking into account the nature of the condition to be treated. 
Overall, the workshop offered an intimate opportunity for both the naïve and experienced 
participants to make connections and generate collaborative relationships with colleagues in 
the field.  It served as an introduction to clinical and regulatory challenges in developing age 
appropriate dosage forms for the participants new to this field. While the moderated 
interactive sessions and small group work incorporated the experiences of participants from 
industry, academia, clinical and regulatory.  
 
The main conference was opened with the plenary talk from Dr Marc Lallemant, (Drugs for 
Neglected Diseases Initiative, Geneva) on refocusing R&D of paediatric HIV formulations on 
the needs of children in resource poor setting. While overall the pipeline for children looks 
encouraging, the short- and medium-term requirements of the youngest children in 
resource-limited settings still badly need to be addressed. Dr Lallement presented the 
barriers faced to access to essential medicines due to factors such as price, missing 
appropriate dosages and formulations or lack of data from pharmacokinetic studies. As to 
way forward, he highlighted that paediatric HIV treatment is an area where multi-sector 
efforts are needed to facilitate development of appropriate formulations,to promote 
manufacturing and supply of paediatric formulations.  The second talk by Daniel 
Schaufelberger (Janssen, US) further emphasized the opportunities and challenges in 
paediatric drug development and importance of thinking outside the Europe and US when 
developing medicines for children. He presented the differences in the needs, preferences of 
dosage forms and regulations in China, Japan, India and Latin America. Harmonizing 
regulatory approvals across countries and adoption by country programmes were seen as 
essential steps towards reaching more children and meeting unmet needs. The structural 
legacy of siloed pharmaceutical manufacturing and clinical testing organisations is a one of 
the barrier to innovation and meeting unmet needs in paediatric medicines. It prohibits the 
rapid and flexible evaluation of drug product formulations in clinical studies. These 
challenges particularly impact the effective development of paediatric medicines given the 
need to design and evaluate age-appropriate drug products and have assurances over 
clinical performance and patient acceptability. Dr Peter Scholes (Clinical Quotient, UK) 
presented the application of new approach of real-time adaptive manufacturing for the 
development of patient-centric dosage forms. He shared few case studies to demonstrate 
how real-time manufacturing enables within-study changes in formulation compositions in 
response to arising human clinical data. Pertinent to the development of paediatric 
medicines, formulations can be optimized based on pharmacokinetic, taste and overall 
acceptability assessments. 
 
Though past decade has seen significant improvement in paediatric formulation research, it 
still encounters everyday a constant challenge of formulation, biopharmaceutical and other 
barriers. Focus sessions and case studies were devised around these challenges, which in 
turn match the EuPFI workstreams on Administration Devices, Age appropriate 
formulations, Biopharmaceutics, Excipients and Taste Assessment & Taste Masking.  
 
The age appropriate formulation session chaired by Dr Terry Ernest (GSK, UK) included talks 
by Dr Sandra Klein (University of Greifswald, Germany) and Dr Sara Hanning (UCL School of 
Pharmacy, UK). Dr Hanning highlighted some practical considerations and challenges with 
respect to PIP submissions and paediatric clinical trials during the pharmaceutical 
development phase, using the FP7-funded Clonidine for Sedation of Paediatric Patients in 
the Intensive Care Unit (CloSed) project as case study paediatric patients.  The research 
paper on this study is published in this issue. Dr Klein presented the update on the ongoing 
activity within the AAF workstream. She talked through the food characteristics and 
potential food effects in paediatric patients. To overcome age appropriate formulation-
related issues, many people (healthcare practitioners, parents or patients) have to resort to 
manipulating the dosage form such as, breaking, crumbling or crushing tablets, mixing 
medicines with food or drink. With case examples on Isoniazid, Phenytoin, Atovaquone and 
enteric coated pellets, Dr Klein demonstrated the impact of manipulation particularly co-
administration of medicines with foods (such as apple sauce, pudding) that are commonly 
used to facilitate administration and improve compliance. She highlighted that most of these 
studies are performed in adults and the limitation is that study design did not always mirror 
typical dosing conditions in children. There is insufficient evidence to justify extrapolation of 
existing methods used to predict food effects in adults directly to paediatric populations. 
The questions that remain to be addressed are what kind of supporting studies should be 
done to gain information of food effects in children and if there is a need for establishing 
standardized dosing vehicles?  
 
As part of Excipients session chaired by Dr David Storey (MSD, UK), the update on the 
European Study for Neonatal Excipient Exposure (ESNEE) research initiative was presented 
by Dr Mark Turner (University of Liverpool, UK).  He provided the insight into the studies 
performed as part this initiative to address the uncertainties in use of excipients in 
paediatrics such as what are the circulating concentrations of commonly used excipients, 
how often are excipients administered to neonates and if we can avoid administering 
excipients. Continuing on this theme of use and acceptability of excipients in children, Smita 
Salunke (UCL School of Pharmacy, UK) presented the update on the ongoing work in 
collaboration with European Medicines Agency (EMA) on compiling the issues, solutions and 
learnings from the PIP applications on the use of excipients in paediatrics. The aim of this 
collaborative work with EMA is to assess the information available through PIP submissions, 
discussions, meeting minutes that are captured in EMA proprietary repository, the 
Paediatric Records Application database (PedRA). The manuscript in preparation will 
summarise the questions raised and discussions on PIPs to support the selection and safety 
of excipients in paediatric. Another aspect in selecting excipients for paediatric medicines is 
its effect on drug absorption. Dr Abdul Basit (UCL School of Pharmacy, UK) presented few 
examples (Polyethylene glycol 400, sorbitol, mannitol) on the influence of solubility-
enhancing excipients and its dose on drug delivery and bioavailability. He highlighted that 
certain excipients in high doses can alter small bowel transit and drug absorption in a 
negative manner while certain excipients in low doses can also increase drug bioavailability. 
However the effect may vary depending on gender. Sex-based analysis of effect of excipients 
on drug absorption was presented.  
 
Dr Jenny Walsh (Jenny Walsh Consulting Ltd, UK) chaired the administration devices session, 
which highlighted the challenges with aerosolized drug delivery in infants and toddlers. 
Thomas Gallem, (PARI Pharma GmbH, Germany) demonstrated the importance of using the 
approaches such as Human Factors Engineering  (HFE) or Usability Engineering (UE) to 
identify the needs of children and understand how they interact with technology, with a 
case example of a facemask.  
 
The taste masking and taste assessment session chaired by Dr Roy Turner (Novartis, Basel) 
embraced the talks on taste perception in children and Pediatric Patient-Reported Outcome 
Instruments for Research to Support Medical Product Labeling.  Measuring acceptability in 
children differs from adult. Children react strongly to sensory properties such taste, texture 
and appearance. Similarly, when assessing younger children’s health status, it is common to 
assess the perspective of informants instead of the children themselves. Informant-reported 
outcome measures may be necessary when children are not able to complete PRO measures 
reliably on their own because of their developmental stage, illness severity, language ability, 
or cognitive functioning. Appropriate methods are needed to developing measures and 
measuring acceptability in children. Judith van der Horst (Wageningen University and 
Research Centre, Netherlands) highlighted the importance of taste and novel methods such 
as Facereader,  Autonomic nervous system and Articulograph for measuring acceptability.  
Dr John Chaplin (University of Gothenburg, Sweden) presented the five Good Research 
Practices for developing measures for children proposed by the ISPOR task force.  
 
Strategies and examples to improve the paediatric drug development through early 
implementation of physiological based pharmacokinetics modeling and simulation (M&S) 
was discussed in the Biopharm session chaired by Dr Hannah Batchelor (University of 
Birmingham, UK). Dr Good (Bristol Myers Squibb, United States) provided critical guidance 
for the design and conduct of pediatric studies as well as the formulation development. He 
emphasized that the employment of M&S in the paediatric area will aid in optimisation of 
drug use and result in minimisation of the number and size of studies needed. Paulien 
Ravenstijn, (Janssen, Belgium) provided the clinical Pharmacological considerations in the 
design of studies in children. 
 
The value of innovation was emphasized by 3 presentations in innovative showcase session. 
Vincenza Pironti, (Adare Pharmaceuticals) provided insight on the increasing role of drug-
delivery systems in solving complex drug administration challenges, such as administration 
of enteric coated multiparticulates through feeding tubes. The company shared the method 
of administering PERT (Pancreatic Enzyme Replacement Therapy) specifically Zenpep® and 
Ultresa® via gastrostomy tubes. Skylar Wolfe (Bristol-Myers Squibb, UK)presented 
development of an age appropriate, palatable powder for oral suspension (PFOS) using a 
robust manufacturing process that can be considered as a platform for future pediatric drug 
development. Eunice Afriyie, (University of Birmingham, UK) provided the independent 
evaluation of different taste masking technologies to enhance the understanding of value of 
each technology, particularly with respect to industrial application and patient need. 
 
The case studies session provided an opportunity for industries to share their challenges and 
experiences in developing paediatric formulations. Albertina Arien (Janssen, Belgium) 
presented the experience of developing a pediatric formulation for a poorly water-soluble 
compound while Gesine Winzenburg, (Novartis, Switzerland) presented case studies on the 
application of taste assesment methods for paediatrics.  
 
Recent advances and trends in paediatric drug-delivery systems were highlighted in the 
selected short talks (soapbox sessions) from submitted abstracts.  60 posters were also 
presented at the meeting all of which provided opportunities for networking and the 
initiation of new collaborations. Poster prizes were awarded for the three best posters 
presented at the meeting. These awards were kindly sponsored by PCCA (Professional 
Compounding Centers of America) and were presented to Heidi Öblom (Åbo Akademi 
University, Finland) for her poster on thin substrates manufactured by the means of 3D 
printing - tailor made drug delivery systems for paediatric use; to Thibault Vallet (ClinSearch) 
for his poster on preliminary development of a tool assessing the acceptability of medicines 
for paediatric use and  Jessica Soto (UCL School of Pharmacy, UK)   for her poster  on 
tasteless  solubilizing excipients to be used with the rat BATA (rief-access taste aversion 
)model to assess the taste of poorly water-soluble drugs. All abstracts are published in this 
special issue. Additionally three presentations selected for full-length manuscripts are 
included in this special issue. 
1. Towards the development of a paediatric biopharmaceutics classification system: 
Results of a survey of experts (1) 
2. Quality and clinical supply considerations of Paediatric Investigation Plans for IV 
preparations - A case study with the FP7 CloSed project (2) 
3. Pharmacy and formulation support for paediatric clinical trials in England (3) 
 
Dr Catherine Tuleu (UCL School of Pharmacy, UK) closed the conference with the remarks of 
thanks to the organisers, sponsors and speakers for making it yet another successful 
conference. The conference helped build stronger and more effective partnerships at local, 
national, regional and global levels, to have more integrated, coherent discussions and to 
share ideas and strategies on addressing issues on developing age appropriate dosage forms 
for children from all substets. More than the closing of an international conference, it was a 
celebration of a new enthusiasm and drive to bring innovative products and advanced 
approaches to improve existing paediatric formulations.  To learn about the progress made 
in development of paediatric formulation join us at the 9th meeting of EuPFI being 
scheduled for the 20–22nd September 2016 in Lisbon, Portugal. We hope to see you there! 
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